新的试验数据表明,免疫药物IMU-856在以便秘方式治疗IBS方面很有希望。 Immunic's drug IMU-856 shows promise in treating IBS with constipation, new trial data suggests.

一家制药公司(Immunic)在一份受人尊敬的医学杂志上公布了其第1/1b阶段对IMU-856号药物试验的数据。 Immunic, a pharmaceutical company, has published data from its Phase 1/1b trial of IMU-856 in a respected medical journal. 试验评估了该药物在便秘治疗肠道感染综合症方面的安全和有效性。 The trial assessed the drug's safety and effectiveness in treating irritable bowel syndrome with constipation. 结果表明,IMU-856可能是一种有希望的治疗,在健康对象和病人中显示出良好的安全和容忍。 Results indicate IMU-856 may be a promising treatment, showing good safety and tolerance in both healthy subjects and patients.

文章

Market Screener

Finanzen

Finanz Nachrichten

-- 显示更少 --

相关故事